Belantamab Mafodotin + Standard Care for Multiple Myeloma

This trial targets individuals with multiple myeloma, a type of blood cancer, that has returned or isn't responding to current treatments. It aims to determine if belantamab mafodotin (an antibody-drug conjugate), administered less frequently with other cancer medicines, can effectively combat the cancer while reducing eye-related side effects. The study includes different groups receiving belantamab mafodotin in combination with either pomalidomide, bortezomib, or carfilzomib, alongside dexamethasone. Those previously treated for multiple myeloma but still experiencing disease progression might be suitable candidates for this trial. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants, offering a chance to contribute to significant findings in cancer treatment.

The trial requires that you stop any systemic anti-myeloma therapy, including chemotherapy and systemic steroids, at least 30 days before starting the study treatment. If you are on any other medications, the protocol does not specify, so it's best to discuss with the trial team.

A previous study found the combination of belantamab mafodotin with pomalidomide and dexamethasone to be generally safe. Most patients tolerated the treatment well, with only a few experiencing serious side effects. However, like many cancer treatments, some patients experienced side effects such as low blood platelet count (thrombocytopenia) and low red blood cell count (anemia).

Research on the combination of belantamab mafodotin with bortezomib and dexamethasone showed that while some serious side effects occurred, many patients still managed the treatment well. Most side effects were manageable, and only a few were severe.

The combination of belantamab mafodotin with carfilzomib and dexamethasone also demonstrated promising safety results. In these studies, most patients experienced mild to moderate side effects, and serious issues were less common.

Researchers are excited about Belantamab Mafodotin for multiple myeloma because it employs a novel mechanism of action compared to current treatments like lenalidomide, bortezomib, and dexamethasone. Unlike these standard therapies, Belantamab Mafodotin is an antibody-drug conjugate that specifically targets and delivers a potent anti-cancer agent directly to the cancer cells, potentially enhancing its effectiveness while minimizing damage to healthy cells. This targeted approach could offer a more precise and powerful option for patients, especially when combined with other medications like pomalidomide, bortezomib, or carfilzomib, as explored in the trial.

This trial will evaluate the effectiveness of belantamab mafodotin combined with different standard care regimens for multiple myeloma. Research has shown that belantamab mafodotin, when used with pomalidomide and dexamethasone, yields promising results for treating multiple myeloma. Specifically, one study found that 71% of patients experienced no cancer worsening over a year. Another study demonstrated that this combination helps control cancer for a longer duration. In this trial, one arm will test belantamab mafodotin with pomalidomide and dexamethasone. Another arm will test belantamab mafodotin combined with bortezomib and dexamethasone, which studies indicate provide significant benefits in both controlling cancer and improving survival rates. The combination with carfilzomib and dexamethasone, tested in a separate arm, showed an 83% overall response rate, indicating a strong cancer-fighting effect. Overall, these combinations suggest that belantamab mafodotin could effectively manage relapsed or resistant multiple myeloma.⁶⁷⁸⁹¹⁰